scholarly journals Recent advances in precision medicine for pancreatic ductal adenocarcinoma

2021 ◽  
Author(s):  
Hiromitsu Hayashi ◽  
Takaaki Higashi ◽  
Tatsunori Miyata ◽  
Yo‐ichi Yamashita ◽  
Hideo Baba
Keyword(s):  
Precision Medicine ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Recent Advances

scholarly journals Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Yiqi Yu ◽  
Gang Yang ◽  
Hua Huang ◽  
Ziyao Fu ◽  
Zhe Cao ◽  
...  
Keyword(s):  
Precision Medicine ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Steady Increase ◽  
Targeted Therapeutics ◽  
Preclinical Models ◽  
High Quality ◽  
Limited Efficacy ◽  
Conventional Regimen ◽  
Challenges And Opportunities

AbstractPancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of PDAC calls for personalized treatment in clinical practice, which requires the construction of a preclinical system for generating patient-derived models. Currently, the lack of high-quality preclinical models results in ineffective translation of novel targeted therapeutics. This review summarizes applications of commonly used models, discusses major difficulties in PDAC model construction and provides recommendations for integrating workflows for precision medicine.

scholarly journals Applied precision medicine in metastatic pancreatic ductal adenocarcinoma

2020 ◽  
Vol 12 ◽  
pp. 175883592093861 ◽  
Author(s):  
Hossein Taghizadeh ◽  
Leonhard Müllauer ◽  
Robert M. Mader ◽  
Martin Schindl ◽  
Gerald W. Prager
Keyword(s):  
Precision Medicine ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Mtor Inhibitor ◽  
Ductal Adenocarcinoma ◽  
Clinical Routine ◽  
Dismal Prognosis ◽  
Frequent Mutations ◽  
Recommended Therapy ◽  
Generation Sequencing

Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) bears a dismal prognosis due to the limited activity of systemic chemotherapy. In our platform for precision medicine, we aim to offer molecular-guided treatments to patients without further standard therapy options. Methods: In this single center, real-world retrospective analysis of our platform, we describe the molecular-based therapy approaches used in all 50 patients diagnosed with therapy-refractory mPDAC. A molecular portrait of the tumor specimens was created by next-generation sequencing, immunohistochemistry (IHC), microsatellite instability (MSI) testing, and fluorescence in situ hybridization. Results: In total, we detected 123 mutations in 50 patients. The five most frequent mutations were KRAS ( n = 40; 80%), TP53 ( n = 29; 58%), CDKN2A ( n = 8; 16%), SMAD4 ( n = 4; 8%), and NOTCH1 ( n = 4; 8%), which together accounted for 40.2% of all mutations. Two patients had gene fusions, namely, TBL1XR1–PIK3CA and EIF3E–RSPO2. IHC detected expression of EGFR, phosphorylated mTOR, and PTEN in 36 (72%), 33 (66%), and 17 patients (34%), respectively. For 14 (28%) of the 50 patients, a targeted therapy was suggested based on the identified molecular targets. The recommended treatments included the mTOR inhibitor everolimus ( n = 3), pembrolizumab ( n = 3), palbociclib ( n = 2), nintedanib ( n = 2), and cetuximab, crizotinib, tamoxifen, and the combination of lapatinib and trastuzumab, in one patient each. Finally, five patients received the recommended therapy. Four patients died due to disease progression before radiological assessment. One patient was treated with nintedanib and achieved stable disease for 6 months. Conclusion: Based on our observations, precision medicine approaches are feasible and implementable in clinical routine and may provide molecular-based therapy recommendations for mPDAC.

scholarly journals Sa1707 – Using Endoscopic Fine Needle Biopsies of Pancreatic Ductal Adenocarcinoma for Immunotherapy Precision Medicine

2019 ◽  
Vol 156 (6) ◽  
pp. S-373
Author(s):  
Eileen Carpenter ◽  
Nina Steele ◽  
Veerin Sirihorachai ◽  
Samantha Kemp ◽  
Lawrence Delrosario ◽  
...  
Keyword(s):  
Precision Medicine ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Fine Needle

scholarly journals Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma

2021 ◽  
Vol 27 (43) ◽  
pp. 7480-7496
Author(s):  
Hiromitsu Hayashi ◽  
Norio Uemura ◽  
Kazuki Matsumura ◽  
Liu Zhao ◽  
Hiroki Sato ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Recent Advances

scholarly journals Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

2016 ◽  
Vol 150 (1) ◽  
pp. 48-63 ◽  
Author(s):  
Erik S. Knudsen ◽  
Eileen M. O’Reilly ◽  
Jonathan R. Brody ◽  
Agnieszka K. Witkiewicz
Keyword(s):  
Genetic Diversity ◽  
Precision Medicine ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E
Sign in / Sign up

Export Citation Format

Share Document